OncoMatch

OncoMatch/Clinical Trials/NCT04787744

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Is NCT04787744 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments for prostate cancer.

Phase 2/3RecruitingVA Office of Research and DevelopmentNCT04787744Data as of May 2026

Treatment: Goserelin, Histrelin, Leuprolide & Triptorelin · ADT + Nilutamide, Flutamide, & Bicalutamide · Degarelix & Relugolix · ADT + Docetaxel +/- prednisone · ADT + Abiraterone + Prednisone · ADT + Abiraterone + Methylprednisolone · ADT + Apalutamide · ADT + EnzalutamideThis is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: curative-intent local therapy — all sites of prostate cancer

If recurrent, prior curative-intent local therapy to all sites of prostate cancer with either upfront radiotherapy or prostatectomy with or without post-operative radiotherapy.

Cannot have received: radiation therapy

Exception: if prior radiation therapy to any sites requiring PET-directed local therapy or salvage local therapy will lead to prohibitively high risk of toxicity from subsequent local therapy, as determined by the treating radiation oncologist or surgeon/urologist

Prior radiation therapy to any sites requiring PET-directed local therapy or salvage local therapy that will lead to prohibitively high risk of toxicity from subsequent local therapy, as determined by the treating radiation oncologist (if radiation is intended as the study local therapy) or surgeon/urologist (if surgery is intended as the study local therapy).

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • VA Long Beach Healthcare System, Long Beach, CA · Long Beach, California
  • VA Greater Los Angeles Healthcare System, West Los Angeles, CA · West Los Angeles, California
  • Washington DC VA Medical Center, Washington, DC · Washington D.C., District of Columbia
  • Bay Pines VA Healthcare System, Pay Pines, FL · Bay Pines, Florida
  • Edward Hines Jr. VA Hospital, Hines, IL · Hines, Illinois

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify